GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Forward PE Ratio

ANI Pharmaceuticals (ANI Pharmaceuticals) Forward PE Ratio : 14.39 (As of Apr. 28, 2024)


View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Forward PE Ratio?

ANI Pharmaceuticals's Forward PE Ratio for today is 14.39.

ANI Pharmaceuticals's PE Ratio without NRI for today is 71.35.

ANI Pharmaceuticals's PE Ratio for today is 79.71.


ANI Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for ANI Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Forward PE Ratio Chart

ANI Pharmaceuticals Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-04 2022-12 2023-12 2024-04
Forward PE Ratio
23.75 45.87 14.16 7.80 11.66 8.30 9.10 11.67 13.53 14.39

ANI Pharmaceuticals Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 23.75 21.98 49.26 42.74 45.87 27.47 11.72 14.16 10.49 11.56 9.51 7.80 12.64 14.39 12.80 11.66 8.39 8.15 7.81 8.30 9.34 9.57 11.67 17.33 21.10 14.58 13.53 15.24

Competitive Comparison of ANI Pharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Forward PE Ratio falls into.



ANI Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


ANI Pharmaceuticals  (NAS:ANIP) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


ANI Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Executives
Muthusamy Shanmugam director, officer: HEAD OF R&D, COO-NOVITIUM OPS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook officer: SR. VP, GENERAL COUNSEL & SEC. C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis officer: SVP, CHIEF HR OFFICER C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz officer: HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert officer: SVP - CORP. DEV. & STRATEGY C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg officer: SVP, GENERICS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken officer: Vice President, Operations 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard director 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp 10 percent owner
Nikhil Lalwani director, officer: PRESIDENT & CEO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey officer: Vice President and CFO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780